Breckenridge Pharmaceutical and Maiva Pharma Partner to Enhance Injectable Drug Supply

Berkeley Heights, NJ – March 11, 2026 – Breckenridge Pharmaceutical, Inc., a U.S. Subsidiary of Towa International, has announced a strategic partnership with Maiva Pharma Pvt. Ltd. To bolster the supply of sterile injectable products for hospitals and clinics across the United States. This collaboration aims to strengthen Breckenridge’s position as a reliable supplier in the U.S. Hospital market and expand access to critical medications.

Strengthening the Hospital Pharmaceutical Supply Chain

The partnership will leverage Maiva Pharma’s manufacturing expertise in sterile injectable products. Maiva will serve as a key manufacturing partner for several injectable products, increasing Breckenridge’s capacity to meet the demands of healthcare facilities nationwide. Brian Guy, President and Chief Commercial Officer of Breckenridge, emphasized the importance of this collaboration, stating, “Ensuring consistent access to critical care injectables is key for our mission and for the needs of the U.S. Hospital community.” Source

A Three-Faceted Business Model for Breckenridge

This partnership represents a significant step in Breckenridge’s evolution into three distinct healthcare channels: specialty, hospital, and retail. This restructuring is designed to improve the company’s ability to cater to diverse patient needs and provide healthcare providers with effective and affordable treatment options. Source

About Breckenridge Pharmaceutical

Breckenridge Pharmaceutical, Inc. Is the U.S. Arm of Towa International, based in Barcelona, Spain. The company focuses on developing and marketing high-quality, cost-effective generic drugs in the United States. Source They partner with manufacturers globally to bring affordable pharmaceuticals to U.S. Patients.

About Maiva Pharma

Maiva Pharma is a leading manufacturer of sterile injectable products, supplying over 45 products to the U.S. Market. With over three decades of experience in sterile manufacturing, Maiva operates two state-of-the-art facilities near Bengaluru, India, employing approximately 1,200 professionals. Source The company’s capabilities include liquid, lyophilized, and suspension injectables in vials, as well as IV bags, with plans to expand into prefilled syringes and cartridge systems.

Key Takeaways

• Breckenridge Pharmaceutical and Maiva Pharma have formed a strategic partnership to increase the supply of sterile injectable drugs to U.S. Hospitals, and clinics.
• The collaboration strengthens Breckenridge’s position in the hospital market and supports its transition to a three-channel business model (specialty, hospital, and retail).
• Maiva Pharma brings extensive expertise in sterile injectable manufacturing to the partnership.

This partnership reflects a continued investment in the hospital pharmaceutical supply chain, aiming to ensure consistent access to critical medications for patients nationwide.